Deal facts
- Buyer
- CorMedix Inc.
- Target
- Substantially all assets of Heron Therapeutics, Inc.
- Deal value
- USD 222,600,000
- Announced
- 9 November 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash, shares, earn-out
Sources
CorMedix Inc. (Nasdaq: CRMD) and Heron Therapeutics, Inc. (Nasdaq: HRTX) announced on 9 November 2026 that they had entered into a definitive asset purchase agreement, signed on 8 November 2026. Under it, CorMedix will acquire substantially all of Heron's assets and assume certain of its liabilities. Excluded assets include Heron's federal income tax net operating loss carryforwards and certain other tax attributes. The assets include four commercial-stage products: ZYNRELEF (bupivacaine and meloxicam) for postoperative pain, APONVIE (aprepitant) for postoperative nausea and vomiting, and CINVANTI (aprepitant) and SUSTOL (granisetron) for chemotherapy-induced nausea and vomiting.
The upfront consideration is $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock. Of the cash, $2.0 million goes into escrow with Citibank, N.A. to secure post-closing adjustments, which may not exceed $10.0 million in either direction. The share count was set by dividing $105 million by $7.20 per share and is fixed, so it does not move with CorMedix's share price before closing. Using CorMedix's $5.32 close on 6 November 2026, the companies value the stock at about $77.6 million and the upfront package at about $222.6 million. That aggregate is a market-price estimate, not a fixed sum.
Heron can also earn up to $55 million in contingent payments tied to calendar 2028 ZYNRELEF net sales: $25 million at $65 million or more, and a further $30 million at $95 million or more. In addition, Heron is due a 5% royalty on combined annual net sales of CINVANTI, SUSTOL and the products under its multi-product Development and License Agreement above $25 million in each of 2027, 2028 and 2029. Concurrently with signing, CorMedix entered into a new $150 million senior secured term loan facility with funds managed by Pharmakon Advisors and says it will draw $75 million of it to support the transaction. Heron intends to repay its Hercules working capital facility from proceeds, and Rubric Capital Management has agreed to exchange $35.0 million of Heron convertible notes due 2031, plus accrued interest, for CorMedix shares that Heron receives.
The deal needs approval from a majority of Heron's outstanding common stock and expiry or termination of the Hart-Scott-Rodino waiting period. Holders of about 22% of Heron's shares, including Rubric, have signed voting agreements in favour. There is no financing condition, and CorMedix expects closing in the first quarter of 2027. Heron owes CorMedix a $4.0 million termination fee in specified circumstances, such as terminating to accept a superior proposal. Heron says it will not liquidate and will remain a publicly traded company.
The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.
Deal timeline
1 update- Firm intention
CorMedix Inc. firm intention to acquire Heron Therapeutics, Inc.
Item 1.01 Entry into a Material Definitive Agreement. Asset Purchase Agreement On November 8, 2026, Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and CorMedix Inc., a Delaware corporation (the “Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company has agreed to sell substantially all of its assets to the Buyer, other than ce
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
BioNTech US Inc. to acquire a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc.
BioNTech US Inc. has agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc. for $205 million in cash. Scholar Rock Inc. is a wholly owned…
- Buyer
- BioNTech US Inc.
- Target
- Rare Pediatric Disease Priority Review Voucher of Scholar Rock Inc.
- Deal value
- USD 205,000,000
- Deal type
- asset sale
Abeona Therapeutics Inc. acquires APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
Abeona Therapeutics Inc. bought substantially all assets related to the research, development, manufacture and commercialization of APT-1011 from Ellodi Pharmaceuticals,…
- Buyer
- Abeona Therapeutics Inc.
- Target
- APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
- Deal value
- USD 20,000,000
- Deal type
- asset sale
Rockwell Medical, Inc. to acquire Vantive's in-center hemodialysis business
Rockwell Medical, Inc. signed an Equity and Asset Purchase Agreement on November 2, 2026 with Vantive Limited, a Jersey company, to acquire Vantive's in-center hemodialy…
- Buyer
- Rockwell Medical, Inc.
- Target
- Vantive in-center hemodialysis business
- Deal value
- USD 125,000,000
- Deal type
- asset sale
Biossil Labs Inc. to acquire Theriva Biologics' ribaxamase and SYN-006 assets
Theriva Biologics, Inc. (NYSE American: TOVX) sold its ribaxamase program to Biossil Labs Inc., a corporation organized under the laws of Canada, under an Asset Purchase…
- Buyer
- Biossil Labs Inc.
- Target
- Theriva Biologics ribaxamase and SYN-006 assets
- Deal value
- USD 350,000
- Deal type
- asset sale
VoxelDox Therapeutics, Inc. to acquire Imunon, Inc.
VoxelDox Therapeutics, Inc. has agreed to acquire assets from Imunon, Inc. in a transaction announced on 21 October 2026. Both companies are based in the United States a…
- Buyer
- VoxelDox Therapeutics, Inc.
- Target
- Imunon, Inc.
- Deal value
- Not disclosed
- Deal type
- asset sale
Buyer history
CorMedix Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive